Sugi Predict

Sugi Predict / Compounds / SCHEMBL400005

SCHEMBL400005

SCHEMBL400005

Nn1cc(Br)c(=O)[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 1.00
▸ GRIA1 P42261 1/20 0.45
▸ GRIA2 P42262 1/20 0.45
▸ GRIA4 P48058 1/20 0.45
▸ GRIK5 Q16478 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CRBN Q96SW2 1/20 0.40
▸ SQOR Q9Y6N5 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ PYGM P11217 1/20 0.36
▸ ASAH1 Q13510 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646139 0.74 TDP1 (0.59) TDP1ALDH1A1POLBCRBN
SCHEMBL28179393 0.73 TDP1 (0.57) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL35345 0.73 TDP1 (0.57) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL9192590 0.73 TDP1 (0.57) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL9192075 0.73 TDP1 (0.57) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL22114444 0.73 TDP1 (0.57) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL9190653 0.73 TDP1 (0.57) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL11144152 0.71 TDP1 (0.55) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL3220656 0.71 TDP1 (0.55) TDP1GRIA1GRIA2GRIA4GRIK5
SCHEMBL17041835 0.70 TDP1 (0.53) TDP1GAAKMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 — — EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US claimed
CN-112638362-B Dry powder formulations of messenger RNA 川斯勒佰尔公司 2025-06-13 — — CN disclosed
CN-119454644-A Improved MRNA loaded lipid nanoparticles and methods of making same 川斯勒佰尔公司 2025-02-18 — — CN disclosed
CN-114390921-B Improved MRNA loaded lipid nanoparticles and methods of making same 川斯勒佰尔公司 2024-11-08 — — CN disclosed
CN-118436618-A Messenger RNA vaccine and use thereof 川斯勒佰尔公司 2024-08-06 — — CN disclosed
CN-112384205-B Messenger RNA vaccine and use thereof 川斯勒佰尔公司 2024-05-03 — — CN disclosed
CN-117136182-A Cationic lipids based on \"God\" buffers 翻译生物公司 2023-11-28 — — CN disclosed
CN-116507606-A TES-based cationic lipids 翻译生物公司 2023-07-28 — — CN disclosed
CN-116457027-A Piperazine-based cationic lipids 翻译生物公司 2023-07-18 — — CN disclosed
CN-1898201-A Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents SENTION INC (US) 2007-01-17 — — CN disclosed
EP-1689704-A2 CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS CoLucid Pharmaceuticals, Inc. (US) 2006-08-16 — — EP disclosed
WO-2005042475-A2 CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS SENTION, INC. (US) 2005-05-12 — — WO disclosed
US-20050096387-A1 Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents SENTION, INC. (US) 2005-05-05 — — US disclosed
EP-0425669-B1 1-AMINO-5-HALOGENOURACILS, PROCESS FOR THEIR PREPARATION, AND CENTRAL NERVOUS SYSTEM DEPRESSANTS CONTAINING SAME AS ACTIVE INGREDIENT YAMASA SHOYU KK (JP) 1995-01-25 — — EP disclosed
US-5334593-A Anxiolytic drugs YAMASA SHOYU KABUSHIKI KAISHA (JP) 1994-08-02 — — US disclosed
US-5252576-A 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient YAMASA SHOYU KABUSHIKI KAISHA (JP) 1993-10-12 — — US disclosed
EP-0509098-A1 ATARACTIC Yamasa Shoyu Kabushiki Kaisha (JP) 1992-10-21 — — EP disclosed
EP-0425669-A1 1-AMINO-5-HALOGENOURACILS, PROCESS FOR THEIR PREPARATION, AND CENTRAL NERVOUS SYSTEM DEPRESSANTS CONTAINING SAME AS ACTIVE INGREDIENT Yamasa Shoyu Kabushiki Kaisha also trading as Yamasa Corporation (JP) 1991-05-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096387-A1 Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents ACHE, BCHE, CHAT TDP1 1097/4885GRIA1 1565/4885GRIA2 1427/4885
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 TDP1 1722/4885GRIA1 108/4885GRIA2 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.